Overview
Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)
Status:
Suspended
Suspended
Trial end date:
2004-02-01
2004-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AstraZeneca
Criteria
Inclusion Criteria:- Newly diagnosed metastatic renal cell carcinoma
- Suitable for nephrectomy
Exclusion Criteria:
- Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma
or within the last 3 years for any other cancer
- Significant cardiac event within 3 months of entry
- Any history of coronary angioplasty or history of myocardial infarction